{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:35:40Z","timestamp":1790368540657,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10157-012-0620-8","type":"journal-article","created":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T00:10:23Z","timestamp":1332720623000},"page":"490-494","source":"Crossref","is-referenced-by-count":28,"title":["A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin"],"prefix":"10.1007","volume":"16","author":[{"given":"Isao","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"620_CR1","doi-asserted-by":"crossref","unstructured":"Maindrault-Goebel F, Louvet C, Andr\u00e9 T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer. 1999;35:1338\u201342.","DOI":"10.1016\/S0959-8049(99)00149-5"},{"key":"620_CR2","first-page":"23","volume":"16","author":"C Twelves","year":"2002","unstructured":"Twelves C. Can capecitabine replace 5-FU\/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology. 2002;16:23\u20136.","journal-title":"Oncology"},{"key":"620_CR3","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938\u201347.","journal-title":"J Clin Oncol"},{"key":"620_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","volume":"29","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29:11\u201320.","journal-title":"Semin Oncol"},{"key":"620_CR5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4143\/crt.2010.42.1.18","volume":"42","author":"HH Lee","year":"2010","unstructured":"Lee HH, Hur H, Kim SH, Park AR, Kim W, Jeon HM. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat. 2010;42:18\u201323.","journal-title":"Cancer Res Treat"},{"key":"620_CR6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(99)03827-1","volume":"354","author":"J Desrame","year":"1999","unstructured":"Desrame J, Broustet H, de Darodes Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999;354:1179\u201380.","journal-title":"Lancet"},{"key":"620_CR7","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/annonc\/mdf311","volume":"13","author":"G Pinotti","year":"2002","unstructured":"Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol. 2002;13:1951\u20132.","journal-title":"Ann Oncol"},{"key":"620_CR8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00280-003-0731-8","volume":"53","author":"RD Hofheinz","year":"2004","unstructured":"Hofheinz RD, Nguyen XD, Buchheidt D, Kerowgan M, Hehlmann R, Hochhaus A. Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient. Cancer Chemother Pharmacol. 2004;53:276\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"620_CR9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ndt\/gfh826","volume":"20","author":"J Labaye","year":"2005","unstructured":"Labaye J, Sarret D, Duvic C, Herody M, Didelot F, Nedelec G, et al. Renal toxicity of oxaliplatin. Nephrol Dial Transplant. 2005;20:1275\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"620_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-6-5","volume":"6","author":"I Dahabreh","year":"2006","unstructured":"Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006;6:5.","journal-title":"BMC Clin Pharmacol"},{"key":"620_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CAD.0b013e3280102f4b","volume":"18","author":"S Buti","year":"2007","unstructured":"Buti S, Ricc\u00f2 M, Chiesa MD, Copercini B, Tomasello G, Brighenti M, et al. Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report. Anticancer Drugs. 2007;18:297\u2013300.","journal-title":"Anticancer Drugs"},{"key":"620_CR12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s12032-009-9263-3","volume":"27","author":"A Ulusakarya","year":"2010","unstructured":"Ulusakarya A, Misra S, Haydar M, Habert H, Castagne V, Gumus Y, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol. 2010;27:1425\u20136.","journal-title":"Med Oncol"},{"key":"620_CR13","first-page":"25","volume":"8","author":"H Chaplin Jr","year":"1973","unstructured":"Chaplin H Jr. Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias. Prog Hematol. 1973;8:25.","journal-title":"Prog Hematol"},{"key":"620_CR14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1537-2995.2010.02600.x","volume":"50","author":"R Font\u00e3o-Wendel","year":"2010","unstructured":"Font\u00e3o-Wendel R, Hoff PM, Lazar A, Freitas D, Novis Y, Patah P, et al. Immune-mediated pancytopenia induced by oxaliplatin: a case report. Transfusion. 2010;50:1453\u20139.","journal-title":"Transfusion"},{"key":"620_CR15","doi-asserted-by":"crossref","first-page":"207084","DOI":"10.1155\/2010\/207084","volume":"2010","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:207084.","journal-title":"Met Based Drugs"},{"key":"620_CR16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141\u20135.","journal-title":"J Clin Oncol"},{"key":"620_CR17","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1053\/ajkd.2001.21361","volume":"37","author":"KM Chow","year":"2001","unstructured":"Chow KM, Lai FM, Wang AY, Chan YL, Tang NL, Li PK. Reversible renal failure in paroxysmal nocturnal hemoglobinuria. Am J Kidney Dis. 2001;37:E17.","journal-title":"Am J Kidney Dis"},{"key":"620_CR18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ki.1993.78","volume":"43","author":"N Honda","year":"1993","unstructured":"Honda N, Hishida A. Pathophysiology of experimental nonoliguric acute renal failure. Kidney Int. 1993;43:513\u201321.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-012-0620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-012-0620-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-012-0620-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:44:32Z","timestamp":1559112272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-012-0620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1007\/s10157-012-0620-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}